AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AstraZeneca on Thursday struck a $1 billion deal to buy a maker of drug for rare diseases, further building out the capabilities it acquired in the 2021 deal for Alexion Pharmaceuticals.

AstraZeneca strikes $1 billion deal for rare-disease drug maker

AstraZeneca PLC (LSE:AZN) has agreed to buy France-based Amolyt Pharma for $1.05 billion (£780 million) to strengthen the late-stage drug pipeline of its Alexion rare disease arm. Lyon-based Amolyt's lead drug is called eneboparatide (AZP-3601), a treatment for hyperparathyroidism that is currently in Phase III trials.

AstraZeneca to buy France's Amolyt Pharma for £780m

AstraZeneca will acquire Amolyt Pharma for up to $1.05 billion in total consideration The transaction is expected to close in the third quarter of 2024 LYON, France and CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential milestone payment of $250 million.

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

Drugmaker AstraZeneca said on Thursday it will acquire rare endocrine diseases-focused firm Amolyt Pharma for $1.05 billion in cash, in a bid to boost its rare diseases portfolio.

AstraZeneca to buy Amolyt Pharma for $1.05 bln to boost rare diseases portfolio

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE® (budesonide/glycopyrronium/formoterol fumarate, or BGF) on severe cardiopulmonary outcomes, including death*, in people with chronic obstructive pulmonary disease (COPD) who also have elevated cardiopulmonary risk, irrespective of their exacerbation history.1 Also, the first participants have been dosed i.

AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD

Ambev

Alibaba

Baidu

British American Tobacco

Anheuser-Busch InBev

GlaxoSmithKline

Imperial Brands PLC

JD.com

Kao Corp

Kone Oyj

Medtronic

Nestle SA

Omron Corp

Pernod Ricard SA

Reckitt Benckiser Group PLC

Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your time for further analysis.

International Wide-Moat Stocks On Sale - The March 2024 Heat Map

AstraZeneca PLC has seen a modest 3% price rise in the past year, but there are positive factors that could drive price upside in 2024. The company has improved revenue guidance for 2024, after guidance beating 2023 numbers. It also sustains a healthy EPS guidance. Recently received approvals in the U.S. and China can prop up revenue growth, and its continued dividend payouts and attractive forward P/E can positively impact the stock price.

5 Reasons AstraZeneca Stock Can Rise In 2024

Sanofi

AstraZeneca and Sanofi's antibody therapy was 90% effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV), a study by the U.S. Centers of Disease Control and Prevention showed on Thursday.

Astra-Sanofi's RSV therapy 'highly effective' against infant hospitalizations, CDC study shows

The government also said AstraZeneca and the U.K. Health Security Agency plan to partner “to advance science for developing and evaluating vaccines.”

AstraZeneca Announed Further GBP200 Million Investment Announced to Expand Presence in Cambridge

AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on Wednesday as part of Finance Minister Jeremy Hunt's spring budget.

AstraZeneca to invest 650 million pounds in UK to boost 'pandemic preparedness'

Chancellor Jeremy Hunt also announced that British pharma giant AstraZeneca PLC (LSE:AZN) plans to invest £650 million in UK life sciences. Under levelling-up plans, AstraZeneca will develop a vaccine manufacturing facility in Liverpool.

AstraZeneca to invest £650mln in UK life sciences

BOSTON--(BUSINESS WIRE)--The Renewable Thermal Collaborative recently released a case study on the first-of-its-kind partnership between AstraZeneca and Vanguard Renewables to enable the delivery of renewable natural gas (RNG) to all of AstraZeneca's sites in the United States by 2026. The partnership will enable as much as 650,000 million British thermal units (MMBTu) per year of RNG to be used across AstraZeneca's U.S. sites, equivalent to the energy required to heat more than 17,800 U.S. hom.

Renewable Thermal Collaborative Releases Case Study on the U.S. Renewable Natural Gas (RNG) Agreement between AstraZeneca and Vanguard Renewables

TOKYO & MUNICH--(BUSINESS WIRE)--The European Medicines Agency (EMA) has validated two marketing authorization applications (MAAs) for Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) datopotamab deruxtecan (Dato-DXd) in two types of cancer. One MAA is for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment. The other MAA is for the treatment of adult patients.

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

U.S. District Judge Colm Connolly's decision comes one day before manufacturers have to respond to Medicare's initial price offers for their drugs.

Judge rejects AstraZeneca's challenge to Medicare drug price negotiations

Apple

Amazon

ASML Hld

Alphabet

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Microsoft

Netflix

NVIDIA

Novo Nordisk

Novartis

Roche Holding AG

SAP SE

Tesla

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

Lockheed Martin

Newmont Mining

Even after aggressive contractionary monetary policies by the federal reserve, inflation has remained relatively stubborn. Supply-chain issues and an increase in price of agricultural commodities are some factors that have contributed to high inflation.

3 Inflation-Resilient Stocks to Weather the Economic Turbulence

NASHVILLE, Tenn.--(BUSINESS WIRE)--Sarah Cannon Research Institute (SCRI), one of the world's leading oncology research organizations conducting community-based clinical trials, announced today a collaboration with AstraZeneca, a global, science-led biopharmaceutical company, aimed at advancing innovative technology and operational synergies to enhance the delivery of oncology clinical trials. Working together, SCRI and AstraZeneca will implement modern solutions to accelerate clinical trial de.

SCRI Announces a Collaboration with AstraZeneca Focused on Technology Enhancements & Innovative Operational Model to Advance Cancer Research

FibroGen

FibroGen Inc said on Monday it is regaining rights to the anemia drug, roxadustat, from AstraZeneca after the companies mutually agreed to terminate their collaboration agreement.

FibroGen regains rights to anemia drug from AstraZeneca

There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.

Move Over Magnificent 7, Say Hello to the GRANOLAS

Sodexo and AstraZeneca extend their global partnership for a further 5 years. Issy les Moulineaux, February 22, 2024 Sodexo reinforces its contract of Food and Facilities Management Services with AstraZeneca in the UK, Sweden, Denmark, Finland, and Norway for a further 5-year period.

Sodexo and AstraZeneca extend their global partnership for a further 5 years.

AstraZeneca's (LON: AZN) stock surged on the FTSE 100 index following the announcement of the approval of its lung-cancer drug Tagrisso, in combination with chemotherapy. AstraZaneca's shares were up by 3%, or 304.0 pence, reaching 10,398 pence.

AstraZeneca's stock surges on FTSE 100 on Tagrisso approval

AstraZeneca PLC (LSE:AZN) is set to see a sales boost from new lung cancer treatments, according to UBS analysts, after the pharmaceuticals firm updated on two treatments on Monday. UBS anticipated peak sales of US$2.5 billion for Dato-DXd, which saw its application accepted by the US Food and Drug Administration on Monday.

AstraZeneca's new lung cancer drugs to boost sales - UBS

AstraZeneca PLC (LSE:AZN) shares swung 4% higher on Monday after it emerged that blockbuster drug Tagrisso (osimertinib), with the addition of chemotherapy, has been approved in the US for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). The approval followed a priority review by the Food and Drug Administration (FDA) based on the results from the FLAURA2 Phase III trial published in The New England Journal of Medicine.

AstraZeneca rallies as results show Tagrisso slows lung cancer progression

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca's (LSE/STO/Nasdaq: AZN) Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the U.S. for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) who have received prior systemic therapy. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly develo.

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

A combination of AstraZeneca's blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer has been approved by the U.S. Food and Drug Administration (FDA), the company said in a statement on Friday.

U.S. FDA approves AstraZeneca's Tagrisso-chemo combo

News for AstraZeneca Stock (AZN)